Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0ZMVEM
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Cetuximab based antibody-drug conjugate
|
|||||
| Synonyms |
Cetuximab based antibody-drug conjugate (AvidBiologics); EGFR antibody-drug conjugate (AvidBiologics)
Click to Show/Hide
|
|||||
| Organization |
Bristol-Myers Squibb FCT bta, Inc.; Bristol Myers Squibb Co.
|
|||||
| Drug Status |
Terminated
|
|||||
| Indication |
In total 2 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Terminated
Squamous cell cancer [ICD11:2D60-2D61]
Terminated
|
|||||
| Drug-to-Antibody Ratio |
2-5
|
|||||
| Structure |
|
|||||
| Antibody Name |
Cetuximab
|
Antibody Info | ||||
| Antigen Name |
Epidermal growth factor receptor (EGFR)
|
Antigen Info | ||||
| Payload Name |
Mertansine DM1
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through nucleophilic lysines.
|
|||||
| Combination Type |
Emtansine
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.